357263-39-9

Basic information

• Product Name: (R)-2-METHYL-4-BENZOYLPIPERAZINE
• Synonyms: (R)-1-BENZOYL-3-METHYLPIPERAZINE;(R)-2-METHYL-4-BENZOYLPIPERAZINE;Methanone, [(3R)-3-Methyl-1-piperazinyl]phenyl-
• CAS NO: 357263-39-9
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.27
• Mol File: 357263-39-9.mol

Chemical Properties

• Boiling Point: 345.3°Cat760mmHg
• Flash Point: 162.6°C
• Appearance: /
• Density: 1.071g/cm³
• Vapor Pressure: 6.2E-05mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: (R)-2-METHYL-4-BENZOYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-METHYL-4-BENZOYLPIPERAZINE(357263-39-9)
• EPA Substance Registry System: (R)-2-METHYL-4-BENZOYLPIPERAZINE(357263-39-9)

Safety Data

• Hazardous Substances Data: 357263-39-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-METHYL-4-BENZOYLPIPERAZINE is used as a pharmacological agent for its potential as a serotonin reuptake inhibitor, which may contribute to the treatment of various mood and anxiety disorders by increasing the availability of serotonin in the synaptic cleft.
(R)-2-METHYL-4-BENZOYLPIPERAZINE is also used as a potential antipsychotic agent, indicating its possible role in managing the symptoms of psychotic disorders by affecting the neurotransmission in the brain.
Additionally, due to its chiral nature, the (R)-enantiomer of (R)-2-METHYL-4-BENZOYLPIPERAZINE is specifically used in research to explore the differences in biological activity between enantiomers, which is crucial for the development of more effective and safer medications.

InChI:InChI=1/C12H16N2O/c1-10-9-14(8-7-13-10)12(15)11-5-3-2-4-6-11/h2-6,10,13H,7-9H2,1H3/t10-/m1/s1

Upstream product

• 93-58-3 benzoic acid methyl ester 
• 75336-86-6 (2R)-methylpiperazine 
• 98-88-4 benzoyl chloride 
• 474010-60-1 (R)-3-methyl-N-benzoylpiperazine hydrochloride 

Downstream Products

• 1173176-87-8 C₁₉H₁₉N₃O₄S₂ 
• 357262-96-5 4-benzoyl-2-(R)-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357263-05-9 4-benzoyl-1-[(4-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357263-13-9 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357262-90-9 4-benzoyl-2-(R)-methyl-1-[(7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357262-60-3 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione 
• 845654-02-6 (2S)-1-[(2R)-4-Benzoyl-2-methyl-piperazin-1-yl]-2-(quinolin-5-yloxy)-propan-1-one 
• 389629-26-9 3-[2-(4-Benzoyl-2-(R)-methyl-piperazin-1-yl)-2-oxo-acetyl]-1H-indole-7-carboxylic acid methylamide 
• 357262-87-4 1-benzoyl-3-(R)-methyl-4-[(7-chloro-4-azaindol-3-yl)oxoacetyl]piperazine 
• 357262-89-6 1-benzoyl-3-(R)-methyl-4-[(5-chloro-7-methyl-4-azaindol-3-yl)oxoacetyl]piperazine 
• 845654-95-7 1-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-2-bromo-propan-1-one 
• 1133750-26-1 (R)-(4-(8-chloropyrido[3,2-d]pyridazin-5-yl)-3-methylpiperazin-1-yl)(phenyl)methanone 
• 1133750-24-9 (R)-(4-(5-chloropyrido[2,3-d]pyridazin-8-yl)-3-methylpiperazin-1-yl)(phenyl)methanone 
• 1095639-25-0 (R)-(4-(4-chloro-6-fluorophthalazin-1-yl)-3-methylpiperazin-1-yl)(phenyl)methanone 

Relevant articles and documents

ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING

The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.

Phthalazine compounds, compositions and methods of use

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.

PIPERAZINE DERIVATIVES

The present invention relates to a crystalline form of 5-{(1S)-2-[(2R)-4-benzoyl-2-methyl-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-4-methoxy-pyridine-2-carboxylic acid methylamide, processes for the preparation thereof, compositions containing the crystalli

Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120

This paper describes selected modification and structure-activity relationship of the small molecule HIV-1 inhibitor, 4-benzoyl-1 -[(4-methoxy-1-H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806). The results revealed: i) that both the presence and configuration (R vs. S) of the 3-methyl group on the piperazine moiety are important for the antiviral activity, with the 3-(R)-methyl derivatives showing the highest activity; ii) that the electronegativity of the C-4 substituent on the indole or azaindole ring seems to be important for the activity, with a small, electron-donating group such as a fluoro or a methoxy group showing enhanced activity, while a nitro group diminishes the activity; iii) that the N-1 position of the indole ring is not eligible for modification without losing activity; and iv) that bulky groups around the C-4 position of the indole or azaindole ring diminish the activity, probably due to steric hindrance in the binding. We found that a synthetic bivalent compound with two BMS-378806 moieties being tethered by a spacer demonstrated about 5-fold enhanced activity in an nM range against HIV-1 infection than the corresponding monomeric inhibitor. But the polyacrylamide-based polyvalent compounds did not show inhibitory activity at up to 200 nM. The Royal Society of Chemistry 2005.

Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution formulation. However, aqueous suspensions of 2 were poorly bioavailable, indicative of dissolution-limited absorption. The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.